INTEGRA LIFESCIENCES HOLDINGS CORPORATION

Integra LifeSciences Holdings Corporation

Equities

IART

US4579852082

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
28.41 ^USD	-3.30%		-10.18%	-34.76%

Apr. 04	North American Morning Briefing : Focus Turns to -2-	DJ
Apr. 03	Citigroup Upgrades Integra LifeSciences to Neutral From Sell With $38 Price Target	MT

Integra LifeSciences Holdings Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022

April 27, 2022 at 06:00 am EDT

Integra LifeSciences Holdings Corporation reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was USD 376.64 million compared to USD 360.07 million a year ago. Net income was USD 32.9 million compared to USD 45.39 million a year ago. Diluted earnings per share from continuing operations was USD 0.39 compared to USD 0.53 a year ago.

Latest news about Integra LifeSciences Holdings Corporation

North American Morning Briefing : Focus Turns to -2-	Apr. 04	DJ
Citigroup Upgrades Integra LifeSciences to Neutral From Sell With $38 Price Target	Apr. 03	MT
Citigroup Upgrades Integra LifeSciences to Neutral From Sell, Price Target is $38	Apr. 03	MT
Integra LifeSciences Completes Acquisition of Acclarent	Apr. 01	MT
Integra LifeSciences Holdings Corporation acquired 100% stake in Acclarent, Inc. from Ethicon US, LLC for $280 million.	Mar. 31	CI
Integra Lifesciences Launches Micromatrix Flex to Provide Convenient Access to Hard-To-Reach Areas in Complex Cases	Mar. 11	CI
Integra Lifesciences Holdings Insider Sold Shares Worth $305,492, According to a Recent SEC Filing	Mar. 08	MT
Truist Securities Cuts Price Target on Integra LifeSciences Holdings to $41 From $46, Maintains Hold Rating	Mar. 01	MT
Tranche Update on Integra LifeSciences Holdings Corporation's Equity Buyback Plan announced on July 27, 2023.	Feb. 28	CI
Integra LifeSciences Shares Drop Following Q4 Results	Feb. 28	MT
Integra LifeSciences Seeks Acquisitions	Feb. 28	CI
Transcript : Integra LifeSciences Holdings Corporation, Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Integra LifeSciences' Q4 Adjusted Earnings, Revenue Decline	Feb. 28	MT
Integra LifeSciences Holdings Corporation Announces the Retirement of Jan De Witte as Chief Executive Officer	Feb. 28	CI
Integra LifeSciences Holdings Corporation Announces Board Changes	Feb. 28	CI
Integra Lifesciences Holdings Corporation Provides Earnings Guidance for the First Quarter and for the Full Year 2024	Feb. 28	CI
Integra LifeSciences Holdings Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Earnings Flash (IART) INTEGRA LIFESCIENCES HOLDINGS CORPORATION Posts Q4 Revenue $397M, vs. Street Est of $399.2M	Feb. 28	MT
Earnings Flash (IART) INTEGRA LIFESCIENCES HOLDINGS CORPORATION Reports Q4 EPS $0.89, vs. Street Est of $0.90	Feb. 28	MT
Integra LifeSciences Holdings Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Integra LifeSciences Holdings Corporation Appoints Jeffrey Alan Graves on the Compensation Committee of the Board	Feb. 27	CI
Transcript : Integra LifeSciences Holdings Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 10:30 AM	Jan. 10
Truist Securities Adjusts Price Target on Integra LifeSciences to $46 From $44, Maintains Hold Rating	Dec. 22	MT
Truist Adjusts Integra LifeSciences Holdings' Price Target to $44 From $39, Keeps Hold Rating	Dec. 14	MT
Integra LifeSciences Agrees to Buy Acclarent for $275 million at Deal Closing	Dec. 13	MT

Chart Integra LifeSciences Holdings Corporation

Duration

Period

Chart Integra LifeSciences Holdings Corporation

More charts

Company Profile

Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The Company provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, bone grafts, and nerve and tendon repair products.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-06 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Integra LifeSciences Holdings Corporation

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

28.41 USD

Average target price

44.8 USD

Spread / Average Target

+57.69%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
INTEGRA LIFESCIENCES HOLDINGS CORPORATION	-34.76%	2.23B
ABBOTT LABORATORIES	-2.92%	185B
MEDTRONIC PLC	-3.80%	105B
BECTON, DICKINSON AND COMPANY	-5.48%	66.59B
DEXCOM, INC.	+11.22%	54.66B
CENCORA, INC.	+16.74%	47.78B
HOYA CORPORATION	+4.06%	41.26B
WEST PHARMACEUTICAL SERVICES, INC.	+4.56%	26.95B
METTLER-TOLEDO INTERNATIONAL, INC.	+1.64%	26.37B
TERUMO CORPORATION	+12.96%	24.8B

Other Medical Equipment, Supplies & Distribution